Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

StrategyPain ManagementOTCSafety Signal

Omega Pharma recalls Napralief 250mg Tablets due to PIL deficiencies

The recall of Napralief 250mg due to deficiencies in the Patient Information Leaflet poses a risk to Omega Pharma's market position and consumer trust. Competitors may capitalize on this situation, necessitating a proactive response from portfolio teams to mitigate potential impacts.

Published: June 29, 2026
Updated: June 29, 2026
Author: Humanexa Intelligence
Therapeutic area: Pain Management / OTC
Company: Omega Pharma Ltd
Asset: Omega
Score8.2

Signal

Omega Pharma recalls Napralief 250mg Tablets due to PIL deficiencies

Company

Omega Pharma Ltd

Category

Strategy

Therapeutic Area

Pain Management / OTC

Action

Monitor

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

The recall of Napralief 250mg due to deficiencies in the Patient Information Leaflet poses a risk to Omega Pharma's market position and consumer trust. Competitors may capitalize on this situation, necessitating a proactive response from portfolio teams to mitigate potential impacts.

Why it matters

The recall of Napralief 250mg due to deficiencies in the Patient Information Leaflet poses a risk to Omega Pharma's market position and consumer trust. Competitors may capitalize on this situation, necessitating a proactive response from portfolio teams to mitigate potential impacts.

What changed

Safety Signal

Analysis

Omega Pharma Ltd is recalling specific batches of Napralief 250mg Gastro-Resistant Tablets due to missing information in the Patient Information Leaflet.

The recall of Napralief 250mg due to deficiencies in the Patient Information Leaflet poses a risk to Omega Pharma's market position and consumer trust. Competitors may capitalize on this situation, necessitating a proactive response from portfolio teams to mitigate potential impacts.

Monitor for updates on the recall process and any potential regulatory actions or consumer reactions.

Related companies & assets

Companies

  • Omega Pharma Ltd →

Assets

  • Omega →

Sources & Humanexa intelligence

Source links

  • Omega Pharma recalls Napralief 250mg Tablets due to PIL deficiencies ↗

Related Humanexa pages

  • Omega Pharma recalls Napralief 250mg Tablets due to PIL deficiencies →

Related signals

Score8.2

Signal

Study Reveals Barriers to HPV Vaccine Uptake in South Quito, Ecuador

Category

Strategy

Therapeutic Area

Oncology / HPV Vaccine

Action

Monitor

Strategyhigh signal

Study Reveals Barriers to HPV Vaccine Uptake in South Quito, Ecuador

A qualitative study identified key barriers to HPV vaccine uptake among parents and healthcare providers in Quito, Ecuador, including misinformation and fear of side effects.

July 4, 2026Read signal →
Trial SummaryCLN

Phase III

Infectious Disease / Vaccines

Status

Active

Sponsor

GSK

Signal Score

8.2

Strategyhigh signal

Phase III Trial Shows Non-Inferior Immunogenicity of PCV-Free Rotavirus Vaccine in Infants

The Phase III trial demonstrated that the PCV-free Rotarix vaccine achieved non-inferior seroconversion rates compared to the original Rotarix.

July 4, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.